Holen Sie sich die Stockscreener-App
10.36
1.80%
-0.19
Handel nachbörslich:
10.35
-0.010
-0.10%
Schlusskurs vom Vortag:
$10.55
Offen:
$10.55
24-Stunden-Volumen:
1.86M
Relative Volume:
1.20
Marktkapitalisierung:
$3.25B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-15.22
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
+3.50%
1M Leistung:
+7.69%
6M Leistung:
+43.69%
1J Leistung:
+22.46%
1-Tages-Spanne:
$10.35
$10.62
1-Wochen-Bereich:
$9.98
$10.68
52-Wochen-Spanne:
$6.685
$10.68
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Vergleichen Sie AMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
10.36 | 3.31B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
142.77 | 64.42B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.46 | 45.95B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
8.82 | 39.14B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.07 | 22.90B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
456.84 | 20.50B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Amneal Pharmaceuticals Hits New 52-Week High of $10.67 - Markets Mojo
Will Amneal Pharmaceuticals Inc. price bounce be sustainableJuly 2025 Market Mood & AI Driven Stock Price Forecasts - newser.com
Measuring Amneal Pharmaceuticals Inc.’s beta against major indicesJuly 2025 Selloffs & Low Volatility Stock Recommendations - newser.com
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus - Nasdaq
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab) - Stock Titan
Applying Wyckoff theory to Amneal Pharmaceuticals Inc. stockJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
Reversal indicators forming on Amneal Pharmaceuticals Inc. stockEarnings Trend Report & Expert Approved Momentum Ideas - newser.com
Is it time to cut losses on Amneal Pharmaceuticals Inc.Quarterly Portfolio Review & Proven Capital Preservation Methods - newser.com
Using Python tools to backtest Amneal Pharmaceuticals Inc. strategies2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
Sentiment analysis tools applied to Amneal Pharmaceuticals Inc.Portfolio Risk Summary & High Win Rate Trade Tips - newser.com
Technical analysis overview for Amneal Pharmaceuticals Inc. stock2025 Price Momentum & Low Risk Entry Point Guides - newser.com
How to read the order book for Amneal Pharmaceuticals Inc.Trade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Will breakout in Amneal Pharmaceuticals Inc. lead to full recoveryGap Down & Comprehensive Market Scan Insights - newser.com
Amneal Pharmaceuticals Hits New 52-Week High of $10.43 - Markets Mojo
Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR® Biosimilar, Targets Multi-Billion-Dollar Market - MSN
What to expect from Amneal Pharmaceuticals Inc. in the next 30 daysQuarterly Market Review & Accurate Buy Signal Notifications - newser.com
Is Amneal Pharmaceuticals Inc. stock cheap compared to fundamentalsEarnings Growth Report & Safe Entry Zone Identification - newser.com
Chart based exit strategy for Amneal Pharmaceuticals Inc.Market Volume Summary & Smart Investment Allocation Insights - newser.com
What analysts say about Amneal Pharmaceuticals Inc stockGap Up/Gap Down Analysis & Free Take Advantage Of Momentum - earlytimes.in
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - sharewise.com
3 Lesser-Known Healthcare Names With Major Upside in Store - sharewise.com
3 Lesser-Known Healthcare Names With Major Upside in Store - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at $10.36 By Investing.com - Investing.com Canada
Amneal Pharmaceuticals stock hits 52-week high at $10.36 - Investing.com
Published on: 2025-10-01 09:03:57 - newser.com
Amneal to Report Third Quarter 2025 Results on October 30, 2025 - The Manila Times
Global Biopharma Amneal Pharmaceuticals Schedules Q3 2025 Financial Results and Investor Conference - Stock Titan
Amneal Files Xolair Biosimilar In US ‘Earlier Than Expected’ - insights.citeline.com
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.02%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):